Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.

Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ.

Cancer. 2019 Sep 30. doi: 10.1002/cncr.32526. [Epub ahead of print]


An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.

Choi Y, Diefenbach CS.

Expert Rev Hematol. 2019 Oct;12(10):801-808. doi: 10.1080/17474086.2019.1658522. Epub 2019 Sep 5.


Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist.

Carreau NA, Diefenbach CS.

Ther Adv Hematol. 2019 May 3;10:2040620719846451. doi: 10.1177/2040620719846451. eCollection 2019. Review.


CART19 in Hodgkin lymphoma: are we driving the right model?

Diefenbach CS.

Blood. 2018 Sep 6;132(10):982-983. doi: 10.1182/blood-2018-07-864520. No abstract available.


Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies.

Prakash A, Diefenbach CS.

Clin Cancer Res. 2018 Oct 1;24(19):4631-4632. doi: 10.1158/1078-0432.CCR-18-1363. Epub 2018 Jun 8.


Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM.

Blood. 2018 Jul 19;132(3):293-306. doi: 10.1182/blood-2017-10-812701. Epub 2018 Apr 25.


Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.

Lin RJ, Ma H, Guo R, Troxel AB, Diefenbach CS.

Br J Haematol. 2018 Jan;180(2):267-270. doi: 10.1111/bjh.15027. Epub 2017 Nov 16.


Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

Lin RJ, Behera M, Diefenbach CS, Flowers CR.

Blood. 2017 Nov 16;130(20):2180-2185. doi: 10.1182/blood-2017-05-736975. Epub 2017 Aug 16. Review. Erratum in: Blood. 2018 Mar 1;131(9):1037.


Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL.

J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw249. Print 2017 Apr. Review.


Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.

Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED.

Leuk Lymphoma. 2017 Jul;58(7):1607-1616. doi: 10.1080/10428194.2016.1256481. Epub 2016 Nov 20.


Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?

Lin RJ, Diefenbach CS.

Oncology (Williston Park). 2016 Oct 15;30(10):914-20. Review.


Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.

Lin RJ, Moskovits T, Diefenbach CS, Hymes KB.

Blood Cancer J. 2016 Mar 11;6:e402. doi: 10.1038/bcj.2016.16. No abstract available.


Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.

Montanari F, Diefenbach CS.

Clin Adv Hematol Oncol. 2015 Aug;13(8):518-24. Review.


Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH.

Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7.


Peripheral T-cell lymphoma: time for a T-cell-centric standard of care.

Saint Fleur-Lominy S, Diefenbach CS.

Oncology (Williston Park). 2013 Sep;27(9):885-6. No abstract available.


Targeting CD30 in hodgkin lymphoma: antibody-drug conjugates make a difference.

Diefenbach CS, Leonard JP.

Am Soc Clin Oncol Educ Book. 2012:162-6. doi: 10.14694/EdBook_AM.2012.32.162.


Mantle cell lymphoma in relapse: the role of emerging new drugs.

Diefenbach CS, O'Connor OA.

Curr Opin Oncol. 2010 Sep;22(5):419-23. doi: 10.1097/CCO.0b013e32833d58f2. Review.


Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J.

Clin Cancer Res. 2008 May 1;14(9):2740-8. doi: 10.1158/1078-0432.CCR-07-4619.


Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J.

Gynecol Oncol. 2007 Feb;104(2):435-42. Epub 2006 Oct 4.


Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.

Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, Bonham L, Singer J, Barakat RR, Aghajanian C, Dupont J.

Cancer. 2006 Oct 1;107(7):1511-9.

Supplemental Content

Loading ...
Support Center